Literature DB >> 17323139

Cytokine secretion profile associated with periportal fibrosis in S. mansoni-infected Egyptian patients.

Roba M Talaat1, Azza I El-Bassiouny, Ahmed M Osman, Magdy Yossif, Ragia Charmy, Maged M Al-Sherbiny.   

Abstract

Periportal fibrosis (PPF) is a major pathological consequence of S. mansoni infection. Ultrasonography is a well-established tool for diagnosis and grading of schistosomiasis-related pathology. This work is performed to study the effect of schistosomiasis mansoni infection on the cytokine secretion profile in S. mansoni-infected patients at various grades of fibrosis, as determined by ultrasonography using Cairo Working Group classification. The levels of IL-2, IL-4, IL5, IL-10, IFN-gamma, and TNF-alpha were measured in the absence of in vitro antigen stimulation and after stimulation with worm and egg antigens. Simple intestinal (INT) patients are characterized by strong proliferation to worm antigen and high levels of IL-10 and TNF-alpha compared to patients at various grades of infection. GradeII (GdII)-infected patients are characterized by higher IL-5 production than are patients with other clinical forms of the disease. Sharp reduction of almost all cytokines in response to both worm and egg antigens was detected in GdIII-infected patients. These results stressed the role of both IL-10 and TNF-alpha in the early stages of hepatic fibrosis, while IL-5 could be employed as a potential predictive marker for advanced stages. In conclusion, PPF is associated with cytokine production profiles that vary with the magnitude of the fibrosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17323139     DOI: 10.1007/s00436-007-0478-y

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  69 in total

1.  Evidence that cellular immune responses to soluble and membrane associated antigens are independently regulated during human schistosomiasis mansoni.

Authors:  L M Bahia-Oliveira; A J Simpson; L F Alves-Oliveira; C Carvalho-Queiroz; A M Silveira; I R Viana; J R Cunha-Melo; P Hagan; G Gazzinelli; R Correa-Oliveira
Journal:  Parasite Immunol       Date:  1996-02       Impact factor: 2.280

2.  Cytokine production in acute versus chronic human Schistosomiasis mansoni: the cross-regulatory role of interferon-gamma and interleukin-10 in the responses of peripheral blood mononuclear cells and splenocytes to parasite antigens.

Authors:  S M Montenegro; P Miranda; S Mahanty; F G Abath; K M Teixeira; E M Coutinho; J Brinkman; I Gonçalves; L A Domingues; A L Domingues; A Sher; T A Wynn
Journal:  J Infect Dis       Date:  1999-06       Impact factor: 5.226

3.  Tumour necrosis factor in hepatosplenic schistosomiasis.

Authors:  K Zwingenberger; E Irschick; J G Vergetti Siqueira; A R Correia Dacal; H Feldmeier
Journal:  Scand J Immunol       Date:  1990-02       Impact factor: 3.487

4.  Immune responses during human schistosomiasis. XII. Differential responsiveness in patients with hepatosplenic disease.

Authors:  D G Colley; A A Garcia; J R Lambertucci; J C Parra; N Katz; R S Rocha; G Gazzinelli
Journal:  Am J Trop Med Hyg       Date:  1986-07       Impact factor: 2.345

Review 5.  Fibrogenic cytokines: the role of immune mediators in the development of scar tissue.

Authors:  E J Kovacs
Journal:  Immunol Today       Date:  1991-01

6.  Murine schistosomiasis mansoni: coordinate cytokine regulation and differences in cellular immune responses of granuloma cells and splenocytes to endogenous and exogenous schistosome egg antigens.

Authors:  C L King; J Xianli; A B Stavitsky
Journal:  Parasite Immunol       Date:  2001-11       Impact factor: 2.280

7.  Release of interleukin 2 and gamma interferon by peripheral mononuclear cells in human Schistosoma mansoni infection normalizes after chemotherapy.

Authors:  K Zwingenberger; E Irschick; J G Siqueira Vergetti; A R Correia Dacal; R Janssen-Rosseck; U Bienzle; C Huber; H Feldmeier
Journal:  Scand J Immunol       Date:  1989-10       Impact factor: 3.487

Review 8.  Cytokines as determinants of resistance and pathology in human Schistosoma mansoni infection.

Authors:  R Corrêa-Oliveira; L C Malaquias; P L Falcão; I R Viana; L M Bahia-Oliveira; A M Silveira; L A Fraga; A Prata; R L Coffman; J R Lambertucci; J R Cunha-Melo; O A Martins-Filho; R A Wilson; G Gazzinelli
Journal:  Braz J Med Biol Res       Date:  1998-01       Impact factor: 2.590

9.  Leukocytes of patients with Schistosoma mansoni respond with a Th2 pattern of cytokine production to mitogen or egg antigens but with a Th0 pattern to worm antigens.

Authors:  M E Williams; S Montenegro; A L Domingues; T A Wynn; K Teixeira; S Mahanty; A Coutinho; A Sher
Journal:  J Infect Dis       Date:  1994-10       Impact factor: 5.226

Review 10.  Lymphokine production by human T cells in disease states.

Authors:  S Romagnani
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

View more
  4 in total

1.  Allograft inflammatory factor-1 alleviates liver disease of BALB/c mice infected with Schistosoma japonicum.

Authors:  Qiong-Rong Chen; Fei Guan; Shu-Mei Song; Jian-Kang Jin; Dan-Sheng Lei; Chun-Mei Chen; Jia-Hui Lei; Zheng-Wang Chen; An-Ou Niu
Journal:  Parasitol Res       Date:  2014-05-10       Impact factor: 2.289

2.  Effect of bisphosphonates treatment on cytokine imbalance between TH17 and Treg in osteoporosis.

Authors:  Roba M Talaat; Asmaa Sidek; Ahmed Mosalem; Ahmed Kholief
Journal:  Inflammopharmacology       Date:  2015-04-25       Impact factor: 4.473

3.  Alterations in immune cell subsets and their cytokine secretion profile in childhood idiopathic thrombocytopenic purpura (ITP).

Authors:  R M Talaat; A M Elmaghraby; S S Barakat; M El-Shahat
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

4.  Effect of chemotherapy with praziquantel on the production of cytokines and morbidity associated with schistosomiasis mansoni.

Authors:  P Martins-Leite; G Gazzinelli; L F Alves-Oliveira; A Gazzinelli; L C C Malaquias; R Correa-Oliveira; A Teixeira-Carvalho; A M S Silveira
Journal:  Antimicrob Agents Chemother       Date:  2008-06-02       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.